Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 94 results for dexamethasone

  1. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

  2. COVID-19 prescribing briefing: corticosteroids

    Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.

  3. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued [GID-TA10353]

  4. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    In development [GID-TA10926] Expected publication date: TBC

  5. Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.

  6. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    In development [GID-TA10502] Expected publication date: TBC

  7. Aflibercept for treating diabetic macular oedema (TA346)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

  8. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.

  9. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  10. Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)

    NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

  11. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]

    In development [GID-TA10477] Expected publication date: TBC

  12. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued [GID-TA10527]

  13. Sore throat (acute): antimicrobial prescribing (NG84)

    This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

  14. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.